Levamisole 3 days
Small molecule
Levamisole 3 days is one of 4 small molecule programs targeting Loiasis. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
3 competitors in Loiasis
#DrugCompanyPhaseTrials
1Stromectol
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Hetrazan
WWyeth-Lederle Vaccines
Approved
Cinqair
TevaPhase 2
Levamisole 3 days
PProgramme National de Lutte contre l'Onchocercose, Republic of the Congo
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Loiasis1 trial
A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
Recruiting·PProgramme National de Lutte contre l'Onchocercose, Republic of the Congo·Phase 2/3·NCT06252961·99 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Levamisole 3 days. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]